Ambrx Biopharma, Inc. shareholders have approved the acquisition proposal from Johnson & Johnson. Under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash upon the closing of the transaction. This acquisition is a strategic move for Johnson & Johnson to expand its portfolio in the field of antibody drug conjugates (ADCs) and other engineered therapies for cancer treatment.